Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of Inpatient Clinical Pharmacists.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Medication Dosing by Advanced Technologies: Promise on the Horizon but Not Without Risk.

Pharmacotherapy·2026
Same author

Creating Solutions to the Challenges in Managing Heparin Infusions: Exploring Use of Technology Including Artificial Intelligence and the Role of Anticoagulation Stewardship.

The Annals of pharmacotherapy·2025
Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025
Same author

Reversing Anticoagulants: Influence of Anticoagulation Stewardship and Key Considerations for Optimizing Outcomes.

The Annals of pharmacotherapy·2025
Same author

International Council for Standardization in Haematology (ICSH) Guidance on the Validation of Laboratory Developed Tests in Haemostasis.

International journal of laboratory hematology·2025

Related Experiment Video

Updated: May 5, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

15.4K

Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.

Robert C Gosselin1, Denis M Dwyre, William E Dager

  • 1University of California-Davis Health System, Sacramento, CA, USA.

The Annals of Pharmacotherapy
|November 22, 2013
PubMed
Summary

The chromogenic ecarin assay (ECA) reliably measures dabigatran levels, offering a valuable tool for clinicians. This assay demonstrates high accuracy and precision, aiding in patient management and drug monitoring.

Keywords:
chromogenic ecarin assaydabigatranlaboratory

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Related Experiment Videos

Last Updated: May 5, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

15.4K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Area of Science:

  • Clinical Chemistry
  • Pharmacology
  • Hematology

Background:

  • Direct thrombin inhibitors like dabigatran require monitoring for accumulation, drug interactions, and clearance.
  • Accurate measurement of dabigatran levels is crucial for safe and effective patient management.
  • The reliability of the chromogenic ecarin assay (ECA) for dabigatran quantification needs further validation.

Purpose of the Study:

  • To evaluate the reliability and performance characteristics of the chromogenic ecarin assay (ECA) for measuring dabigatran concentrations.
  • To assess the precision, linearity, accuracy, and carryover of the ECA method.
  • To compare ECA results with established dilute thrombin time methods and mass spectrophotometry.

Main Methods:

  • The ECA method was evaluated for imprecision, linearity, accuracy, carryover, and lower limits of blank.
  • Normal plasma samples spiked with dabigatran (0-500 ng/mL) were analyzed across three laboratories.
  • Patient trough and peak dabigatran levels were compared with mass spectrophotometry.

Main Results:

  • The ECA demonstrated high linearity (R² = 0.989) and accuracy (R² = 0.985, slope = 0.908) for dabigatran levels between 18 and 470 ng/mL.
  • Within-run and day-to-day imprecision were consistently below 10%.
  • The ECA showed no carryover at 0 ng/mL and was particularly reliable at lower dabigatran concentrations.

Conclusions:

  • The chromogenic ECA is an effective method for quantifying dabigatran levels in clinical settings.
  • The assay's reliability supports its use in monitoring patients on dabigatran therapy.
  • Further research is needed to optimize the clinical application of ECA for reducing thromboembolic and bleeding risks.